Who should decide if a drug is worth the cost?

With our new President in office, the debate continues about America's seemingly unlimited spending on prescription medications and the best ways to control healthcare costs. Scott Gottlieb wrote an op-ed in the Wall Street Journal opposing the strategies he sees President Obama and the new administration considering to solve the problem.  Report.


Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.